Amgen
AMGN
$413.08
+2.60%
Amgen Inc. is one of the world's largest independent biotechnology companies, discovering, developing, manufacturing, and marketing human therapeutics across oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare disease, with a portfolio spanning flagship biologics such as Enbrel, Otezla, Prolia, Repatha, and Tepezza alongside a growing biosimilars franchise. The company is best characterized as an established large-cap biotech platform rather than a high-growth disruptor, distinguished by its scale in biologics manufacturing, an entrenched nephrology and bone-health franchise, and a pipeline now pivoting toward obesity and cardiometabolic disease. The current investor narrative is dominated by the commercial trajectory of MariTide, Amgen's once-monthly obesity candidate, which bulls argue could carve a differentiated niche against Eli Lilly and Novo Nordisk on dosing convenience, while bears question whether Amgen can win share in a market where competitors have deeper metabolic footprints. Sentiment has also been shaped by external policy risk, including the threat of 100% pharmaceutical tariffs on drugmakers without pricing deals, and by regulatory scrutiny surrounding partner drugs such as Tavneos, both of which have injected headline volatility into an otherwise defensive, dividend-paying equity story.…
AMGN
Amgen
$413.08
Related headlines
Investment Opinion: Should I buy AMGN Today?
We assign a Hold rating to Amgen, balancing its defensive dividend yield and pipeline optionality against premium valuation and near-term headwinds. The analyst consensus is Hold (mean recommendation 2.65), with an average target price of $390.94, which is 3.0% below the current price of $403.04, suggesting limited upside. Our thesis is that Amgen is a fairly valued, income-oriented biotech with a promising but unproven obesity asset, and investors are adequately compensated for the risks through a 2.91% dividend yield and low beta of 0.426.
The supporting evidence includes a forward P/E of 16.48, which is reasonable for a large-cap biotech with a 9.68% revenue growth rate and 23.6% net margin. The company generates strong free cash flow of $10.175B TTM, comfortably covering its dividend, and has a robust gross margin of 72.0%. However, the PEG ratio of 0.26 suggests undervaluation relative to growth, but this is offset by a high debt-to-equity ratio of 6.31 and a P/B of 20.34, indicating that the balance sheet is stretched. The stock's 35.52% one-year return has outpaced the S&P 500's 15.01%, but recent underperformance (-8.99% in the past month) highlights waning momentum.
Key risks that could invalidate our Hold rating include: (1) MariTide failing to demonstrate competitive efficacy or safety in upcoming trials, which would remove a key growth catalyst; (2) the imposition of 100% tariffs on Amgen's products, which could significantly impact international revenue and margins; and (3) a deterioration in the balance sheet or a dividend cut due to high leverage. We would upgrade to Buy if the stock pulls back to the $350-$370 range (implying a forward P/E of 12-13x) or if MariTide shows best-in-class data. We would downgrade to Sell if revenue growth decelerates below 5% or if the dividend payout ratio exceeds 80%. Relative to its history and peers, Amgen appears fairly valued, with the market pricing in modest growth and pipeline success.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a balanced risk/reward profile, with its defensive dividend and low beta appealing to income investors, but near-term headwinds from competition, policy, and leverage limit upside. The stock's recent underperformance (-8.99% in the past month) and relative weakness versus the S&P 500 suggest negative momentum, yet the forward P/E of 16.48 and PEG of 0.26 imply the market may be underestimating growth prospects. The key swing factor is MariTide: positive data could catalyze a re-rating toward the bull case, while failure would likely push the stock toward the bear case. We would upgrade to bullish if MariTide shows best-in-class efficacy and tariffs are resolved favorably; we would downgrade to bearish if revenue growth decelerates below 5% or if debt concerns escalate. Overall, we expect the stock to trade in the base case range of $380-$420 over the next 12 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $391.46 and implied upside of -5.2% versus the current price.
Average Target
$391.46
0 analysts
Implied Upside
-5.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$225 - $500
Analyst target range
Bulls vs Bears: AMGN Investment Factors
The bull case for Amgen rests on its defensive characteristics, attractive dividend, and the potential of MariTide to disrupt the obesity market, while the bear case highlights premium valuation, high debt, and competitive and regulatory threats. Currently, the bear evidence appears slightly stronger given the recent 8.99% monthly decline, relative underperformance versus the S&P 500, and a 'hold' analyst consensus with a target price below the current price. The most critical tension is whether MariTide can gain meaningful traction against entrenched competitors; positive clinical data or commercial success could re-rate the stock, while failure would leave Amgen reliant on its mature portfolio and biosimilars. Valuation is stretched on some metrics, but the forward P/E of 16.48 and PEG of 0.26 suggest growth is not fully priced in. Overall, the risk/reward is balanced but tilted slightly negative in the near term due to momentum and policy overhangs.
Bullish
- MariTide obesity optionality: MariTide's once-monthly dosing could differentiate Amgen in the obesity market, where competitors Eli Lilly and Novo Nordisk currently dominate. The recent Zacks article highlights convenience as a potential share driver, and success could add a multi-billion-dollar revenue stream to a company already generating $45.0B in estimated 2026 revenue.
- Strong revenue growth and profitability: Q2 2026 revenue grew 9.68% YoY to $10.05B, with net income of $2.375B (23.6% net margin) and operating income of $3.514B (35.0% operating margin). Gross margin expanded to 72.0% in Q2 2026 from 67.2% in Q2 2025, demonstrating operating leverage.
- Attractive dividend and low beta: AMGN offers a 2.91% dividend yield with a sustainable 66.5% payout ratio, appealing to income investors. Its beta of 0.426 indicates low volatility relative to the market, providing defensive characteristics in uncertain times.
- Undemanding forward valuation: The forward P/E of 16.48 is below the trailing P/E of 22.84, reflecting expected EPS growth to $29.41 in 2026. The PEG ratio of 0.26 suggests the stock is undervalued relative to its growth prospects.
Bearish
- Premium valuation multiples: AMGN trades at a P/B of 20.34 and P/S of 4.79, which are rich compared to the broader healthcare sector. The EV/EBITDA of 13.11 and P/CF of 17.68 suggest the stock is not cheap, leaving little room for error.
- High debt burden: The debt-to-equity ratio of 6.31 is elevated, reflecting significant leverage from the Horizon acquisition. Interest expense of $673M in Q2 2026 consumes a notable portion of operating income, and the current ratio of 1.14 indicates tight liquidity.
- Intense obesity competition: Eli Lilly and Novo Nordisk have established dominant positions in the obesity market, and Pfizer's berobenatide could add further competition. Amgen's late entry and lack of a disclosed comprehensive clinical profile for MariTide create uncertainty about its ability to capture meaningful share.
- Regulatory and policy risks: The threat of 100% pharmaceutical tariffs on drugmakers without pricing deals poses a significant risk to Amgen's international operations. Additionally, regulatory scrutiny on partner drug Tavneos for data manipulation and safety concerns could lead to reputational damage and financial penalties.
AMGN Technical Analysis
Beta
0.41
0.41x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$288-$447
Price range past year
Annual Return
+39.8%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +0.9% |
| 3m | +13.6% | +3.4% |
| 6m | +17.7% | +14.4% |
| 1y | +39.8% | +16.2% |
| ytd | +26.1% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Quarterly Revenue
$10.1B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
72.0%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Amgen's financial risk profile is characterized by high leverage and significant interest obligations. The debt-to-equity ratio of 6.31 is elevated, a consequence of the $27.8B Horizon Therapeutics acquisition, and quarterly interest expense of $673M consumes a substantial 19.1% of operating income. The current ratio of 1.14 indicates limited short-term liquidity, and while free cash flow TTM of $10.175B provides some cushion, the dividend payout ratio of 66.5% leaves little room for error if earnings decline. Additionally, revenue concentration in flagship drugs like Enbrel and Otezla exposes the company to patent cliffs and biosimilar competition, which could pressure margins that are already fluctuating (gross margin ranged from 63.6% to 81.9% over the past eight quarters).
Market and competitive risks are pronounced, particularly in the obesity space where Amgen is a late entrant. Eli Lilly and Novo Nordisk have established dominant positions, and Pfizer's berobenatide could further crowd the market, making it challenging for MariTide to gain share despite its convenience advantage. The threat of 100% pharmaceutical tariffs on companies without pricing deals adds policy uncertainty, and Amgen's international revenue could be adversely affected. Regulatory scrutiny on Tavneos for data manipulation poses reputational and financial risks. With a beta of 0.426, Amgen is less sensitive to market swings, but sector rotation away from healthcare could still weigh on the stock, as evidenced by its 9.58% underperformance versus the S&P 500 in the past month.
The worst-case scenario involves a combination of MariTide clinical failure or poor commercial uptake, escalating tariff implementation, and regulatory penalties from Tavneos, leading to earnings downgrades and multiple compression. In such a scenario, the stock could retest its 52-week low of $288.00, representing a 28.5% decline from the current price of $403.04. The analyst low target of $225.00 implies an even steeper 44.2% downside, though that likely assumes a severe bear case. A more realistic bear scenario might see the stock fall to the $320-$340 range, a 15-20% drop, if growth stalls and sentiment remains negative. Investors should be prepared for potential drawdowns of this magnitude given the stock's historical max drawdown of 16.57% and current negative momentum.
FAQ
The most severe risk is competitive and pipeline risk, specifically MariTide's ability to gain share in the obesity market against Eli Lilly and Novo Nordisk; failure could erase a significant portion of the growth premium. Financial risk is also high, with a debt-to-equity ratio of 6.31 and interest expense consuming 19.1% of operating income, leaving little flexibility if earnings decline. Regulatory and policy risks include the threat of 100% tariffs on drugmakers without pricing deals, which could impact international revenue, and ongoing scrutiny of Tavneos for data manipulation. Finally, market risk is moderate given the low beta of 0.426, but sector rotation away from healthcare could pressure the stock, as seen in the recent 8.99% monthly decline.
Our 12-month forecast for AMGN includes three scenarios: a bull case (25% probability) with a target range of $450-$500, driven by MariTide success and tariff resolution; a base case (55% probability) with a range of $380-$420, assuming steady execution and niche MariTide adoption; and a bear case (20% probability) with a range of $288-$340, triggered by MariTide failure or tariff implementation. The base case is most likely, supported by the analyst average target of $390.94 and the current forward P/E of 16.48. Key assumptions include revenue growth of 6-8% and stable margins. The stock is expected to remain range-bound unless a major catalyst emerges.
AMGN appears fairly valued to slightly overvalued on most metrics. The trailing P/E of 22.84 and forward P/E of 16.48 are in line with large-cap biotech peers, but the P/B of 20.34 and P/S of 4.79 are elevated, reflecting the company's high debt load and acquisition-related goodwill. The PEG ratio of 0.26 suggests undervaluation relative to expected growth, but this is contingent on achieving the $29.41 EPS estimate for 2026. Compared to its own history, the stock is trading at a premium to its 5-year average P/E, implying the market is pricing in successful pipeline execution. If MariTide disappoints, the valuation could compress toward the sector average, implying a stock price in the $350-$370 range.
From a risk/reward perspective, AMGN is a Hold rather than a strong Buy at current levels. The stock trades at $403.04, above the analyst average target of $390.94, implying limited upside, and it has underperformed the S&P 500 by 9.58% in the past month. However, the 2.91% dividend yield and low beta of 0.426 make it attractive for income and defensive investors. The biggest downside risk is MariTide's uncertain commercial prospects, which could lead to a 20-30% decline if disappointing. For long-term investors comfortable with biotech risk, accumulating on dips below $380 could be prudent, but near-term catalysts are mixed.
AMGN is better suited for long-term investment, given its defensive characteristics, dividend yield, and pipeline optionality. The low beta of 0.426 and 2.91% dividend yield appeal to income-focused investors with a horizon of at least 3-5 years, allowing time for MariTide to materialize and debt to be reduced. Short-term trading is less attractive due to the stock's recent negative momentum (-8.99% in one month) and the binary nature of upcoming clinical and regulatory events. A minimum holding period of 2-3 years is recommended to ride out volatility and benefit from potential pipeline successes. However, investors should monitor quarterly earnings and adjust positions if fundamentals deteriorate.